A Global Health Scandal Unfolds: How a Company Linked to a Massive Raid on Illicit Weight-Loss Drugs Continues to Sell Unlicensed Products
In a shocking revelation, an investigation by The Guardian has found that the company linked to the largest global raid on an illicit weight-loss drug facility is still selling unlicensed drugs to thousands of customers. Alluvi Healthcare Limited, which was raided by the Medicines and Healthcare products Regulatory Agency (MHRA) in October, continues to operate a lucrative online business, selling replicas of retatrutide, an experimental injection developed by Eli Lilly that targets three gut hormones.
The company's actions have sparked widespread concern, with many experts warning about the risks associated with buying unregulated weight-loss drugs. These products may not contain the correct ingredients or dosage, and may not be sterilized to the required standard, posing serious health risks to consumers. One person who bought an Alluvi pen reported experiencing severe gastrointestinal issues, unstable energy levels, and dehydration.
The MHRA's failure to comment on this matter has raised questions about its ability to regulate the pharmaceutical industry effectively. The agency's lack of action has also led to concerns that it may be unable to protect consumers from unlicensed weight-loss drugs.
Furthermore, an investigation by Channel 4 found that individuals who spoke negatively about Alluvi had their social media accounts taken over, highlighting the tactics used by companies to silence critics. This is just one example of how illicit production models of weight-loss drugs can be perpetuated through online channels.
As winter approaches, concerns about storing weight-loss injections become increasingly relevant. Experts warn that colder temperatures can pose risks to storage conditions, which could compromise the effectiveness and safety of these products.
In light of this scandal, it is essential for regulatory agencies to take immediate action to protect consumers from unlicensed weight-loss drugs. The MHRA must provide a clear explanation for its inaction and take steps to ensure that companies like Alluvi are held accountable for their actions.
In a shocking revelation, an investigation by The Guardian has found that the company linked to the largest global raid on an illicit weight-loss drug facility is still selling unlicensed drugs to thousands of customers. Alluvi Healthcare Limited, which was raided by the Medicines and Healthcare products Regulatory Agency (MHRA) in October, continues to operate a lucrative online business, selling replicas of retatrutide, an experimental injection developed by Eli Lilly that targets three gut hormones.
The company's actions have sparked widespread concern, with many experts warning about the risks associated with buying unregulated weight-loss drugs. These products may not contain the correct ingredients or dosage, and may not be sterilized to the required standard, posing serious health risks to consumers. One person who bought an Alluvi pen reported experiencing severe gastrointestinal issues, unstable energy levels, and dehydration.
The MHRA's failure to comment on this matter has raised questions about its ability to regulate the pharmaceutical industry effectively. The agency's lack of action has also led to concerns that it may be unable to protect consumers from unlicensed weight-loss drugs.
Furthermore, an investigation by Channel 4 found that individuals who spoke negatively about Alluvi had their social media accounts taken over, highlighting the tactics used by companies to silence critics. This is just one example of how illicit production models of weight-loss drugs can be perpetuated through online channels.
As winter approaches, concerns about storing weight-loss injections become increasingly relevant. Experts warn that colder temperatures can pose risks to storage conditions, which could compromise the effectiveness and safety of these products.
In light of this scandal, it is essential for regulatory agencies to take immediate action to protect consumers from unlicensed weight-loss drugs. The MHRA must provide a clear explanation for its inaction and take steps to ensure that companies like Alluvi are held accountable for their actions.